Download PDF
Thromb Haemost 1992; 68(02): 143-148
DOI: 10.1055/s-0038-1656339
Original Article
Schattauer GmbH Stuttgart

Insights on Monoclonal Antibodies to Kininogens' Heavy Chain Which Influence Kininogens' Binding to Platelets

Yongping Jiang
1   The Thrombosis Research Center and Department of Medicine, Temple University School of Medicine, Philadelphia, PA
2   The Division of Hematology and Oncology, the Department of Internal Medicine, the University of Michigan Medical Center, Ann Arbor, MI, USA
,
Weerasak Nawarawong
1   The Thrombosis Research Center and Department of Medicine, Temple University School of Medicine, Philadelphia, PA
,
Frank J Meloni
1   The Thrombosis Research Center and Department of Medicine, Temple University School of Medicine, Philadelphia, PA
,
Alvin H Schmaier
1   The Thrombosis Research Center and Department of Medicine, Temple University School of Medicine, Philadelphia, PA
2   The Division of Hematology and Oncology, the Department of Internal Medicine, the University of Michigan Medical Center, Ann Arbor, MI, USA
› Author Affiliations
Further Information

Publication History

Received 16 December 1991

Accepted after revision 25 March 1992

Publication Date:
03 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

Purified domains of low molecular weight kininogen (LK) can be used directly to determine the epitopes of monoclonal antibodies (mAbs) that have been shown to influence kininogen function. LK, purified from plasma by carboxymethyl-papain-Sepharose 4B affinity chromatography and kaolin adsorption, was digested by trypsin and chymotrypsin. The domains of LK were then separated by gel filtration followed by carboxymethyl-papain-Sepharose 4B affinity chromatography. Using the purified domains of LK’s heavy chain, the regions on kininogens' heavy chain which various monoclonal antibodies are directed to were determined by enzyme-linked immunosorbent assay and immunoblotting. MAb 2B5 which neutralized kininogens' ability to inhibit calpain cross-reacted with domains 2 and 3. MAb HKH8 which reacted with kininogens' domain 1 and 2 was found to inhibit 125I-HK binding to platelets. At two-fold molar excess, mAb HKH8 was a better inhibitor of 125I-HK binding to platelets than higher concentrations, where the antibody was shown to cause increased binding to platelets. Alternatively, HKH8 F(ab')2 completely inhibited 125I-HK binding to platelets even at high concentrations of antibody. These studies indicate that purified domains of kininogens' heavy chain can be used to rapidly localize epitopes for antibodies. Further, mAb HKH8 should be a valuable probe to understand the mechanisms of kininogens' binding to platelets.

 

  • References

  • 1 Jacobson S. Separation of two different substrates for plasma kinin-forming enzymes. Nature 1966; 210: 98-99
    CrossrefPubMedSearch in Google Scholar
  • 2 Kato H, Nagasawa S, Iwanaga S. HMW and LMW kininogens. Methods Enzymol 1981; 80: 172-198
    PubMedSearch in Google Scholar
  • 3 Müller-Esterl W, Iwanaga S, Nakanishi S. Kininogens revisited. Trends Biochem Sci 1986; 11: 336-339
    CrossrefPubMedSearch in Google Scholar
  • 4 Wiggins RC, Bouma BN, Cochrane CG, Griffin JH. Role of high-molecular-weight kininogen in surface binding and activation of coagulation factor XI and prekallikrein. Proc Natl Acad Sci 1977; 74: 4636-4640
    CrossrefPubMedSearch in Google Scholar
  • 5 Müller-Esterl W, Vohle-Timmermann M, Boos B, Dittman B. Purification and properties of human low molecular weight kininogen. Biochim Biophys Acta 1982; 706: 145-152
    CrossrefPubMedSearch in Google Scholar
  • 6 Takagaki Y, Kitamura N, Nakanishi S. Cloning and sequence analysis of cDNAs for human high molecular weight and low molecular weight prekininogens. J Biol Chem 1985; 260: 8601-8609
    PubMedSearch in Google Scholar
  • 7 Kitamara N, Kitagawa H, Fuknshima D, Takagaki Y, Miyata T, Nakanishi S. Structural organization of the human kininogen and a model for its evolution. J Biol Chem 1985; 260: 8610-8617
    PubMedSearch in Google Scholar
  • 8 Ohkubo I, Kurachi K, Takasawa T, Shiokawa H, Sasahi M. Isolation of human cDNA for alpha-2-thiol protease inhibitor and its identity with low molecular weight kininogen. Biochemistry 1984; 23: 3891-3899
    CrossrefPubMedSearch in Google Scholar
  • 9 Sueyoshi T, Enjoyii K, Shimada T, Kato H, Iwanaga S, Bando Y, Kominami E, Katunuma N. A new function of kininogens as thiol-proteinase inhibitors: inhibition of papain and cathepsins B, H and L by bovine, rat and human plasma kininogens. FEBS Lett 1985; 182: 193-195
    CrossrefPubMedSearch in Google Scholar
  • 10 Müller-Esterl W, Fritz H, Machleidt W, Ritonja A, Brzin J, Kotnik M, Turk V, Kellerman J, Lottspeich F. Human plasma kininogens are identical with -cysteine proteinase inhibitors. FEBS Lett 1985; 182: 310-314
    CrossrefPubMedSearch in Google Scholar
  • 11 Salvesen G, Parkes C, Abrahamson M, Grubb A, Barrett AJ. Human low-Mr kininogen contains three copies of a cystatin sequence that are divergent in structure and in inhibitory activity for cysteine proteinases. Biochem J 1986; 234: 429-434
    CrossrefPubMedSearch in Google Scholar
  • 12 Schmaier AH, Bradford H, Silver LD, Farber A, Scott CF, Schutsky D, Colman RW. High molecular weight kininogen is an inhibitor of platelet calpain. J Clin Invest 1986; 77: 1565-1573
    CrossrefPubMedSearch in Google Scholar
  • 13 Bradford H, Schmaier AH, Colman RW. Kinetics of inhibition of platelet calpain II by human kininogens. Biochem J 1990; 270: 83-90
    CrossrefPubMedSearch in Google Scholar
  • 14 Meloni FJ, Schmaier AH. Low molecular weight kininogen binds to platelets to modulate thrombin-induced platelet activation. J Biol Chem 1991; 266: 6786-6794
    PubMedSearch in Google Scholar
  • 15 Jiang YP, Müller-Esterl W, Schmaier AH. Kininogens' domain 3 contains a cell binding site and a site that modifies thrombin activation of platelets. J Biol Chem 1992; 267: 3712-3717
    PubMedSearch in Google Scholar
  • 16 Overlack A, Stumpe KO, Zyazock W, Ressel C, Druck F. Defect in kallikrein-kinin-systen in essential hypertension and reduction of blood pressure by orally given hallikrein. Adv Exp Med Biol 1979; 120B: 539-547
    PubMedSearch in Google Scholar
  • 17 Wicklmayer M, Dietze G, Meyer L, Bottger J, Grunst J. Inhibition of proton conduction by chemical modification of the membrane moiety of proton translocating ATPase. FEBS Lett 1979; 98: 61-65
    CrossrefPubMedSearch in Google Scholar
  • 18 Colman RW, Bagdasarian A, Talamo RC, Scott CF, Seavey M, Guimares JA, Pierce JV, Kaplan AP. Williams trait: human kininogen deficiency with diminished levels of plasminogen proactivator and prekallikrein associated with abnormalities of the hageman factor-dependent pathways. J Clin Invest 1975; 56: 1650-1662
    CrossrefPubMedSearch in Google Scholar
  • 19 Schmaier AH, Silver L, Adams LA, Fischer CG, Munoz CP, Vroman L, Colman RW. The effect of high molecular weight kininogen on surface-adsorbed fibrinogen. Thromb Res 1984; 33: 51-67
    CrossrefPubMedSearch in Google Scholar
  • 20 Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254
    CrossrefPubMedSearch in Google Scholar
  • 21 Laemmli UK. Cleavage of the structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685
    CrossrefPubMedSearch in Google Scholar
  • 22 Schmaier AH, Colman RW. Platelet high-molecular-weight kininogen. Methods Enzymol 1989; 169: 276-296
    PubMedSearch in Google Scholar
  • 23 Johnson D, Salvesen G, Brown MA, Barrett AJ. Rapid isolation of human kininogens. Thromb Res 1987; 48: 187-193
    CrossrefPubMedSearch in Google Scholar
  • 24 Müller-Esterl W, Johnson DA, Salvesen G, Barrett AJ. Human kininogens. Methods Enzymol 1987; 163: 240-256
    PubMedSearch in Google Scholar
  • 25 Schmaier AH, Schutsky D, Farber A, Silver LD, Bradford HN, Colman RW. Determination of the bifunctional properties of high molecular weight kininogen by studies with monoclonal antibodies directed to each of its chains. J Biol Chem 1987; 262: 1405-1411
    PubMedSearch in Google Scholar
  • 26 Vogel R, Assfalg-Machleidt I, Esterl A, Machleidt W, Müller-Esterl W. Proteinase-sensitive regions in the heavy chain of low molecular weight kininogen map to the inter-domain junctions. J Biol Chem 1988; 263: 12661-12668
    PubMedSearch in Google Scholar
  • 27 Kaufmann J. PhD Thesis. University of Munich; Germany: 1990
    Search in Google Scholar
  • 28 Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci 1979; 76: 4350-4354
    CrossrefPubMedSearch in Google Scholar
  • 29 Gustafson EJ, Schutsky D, Knight LC, Schmaier AH. High molecular weight kininogen binds to unstimulated platelets. J Clin Invest 1986; 78: 310-318
    CrossrefPubMedSearch in Google Scholar
  • 30 Fraker PJ, Speck Jr SC. Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4-6-tetra-chloro-3 alpha, 6 alpha-diphenylglycoluril. Biochem Biophys Res Commun 1978; 80: 849-857
    CrossrefPubMedSearch in Google Scholar
  • 31 Griffin JH, Cochrane CG. Mechanisms for the involvement of high molecular weight kininogen in surface-dependent reactions of hageman factor. Proc Natl Acad Sci 1976; 73: 2554-2558
    CrossrefPubMedSearch in Google Scholar
  • 32 Retzios AD, Rosenfeld R, Schiffman S. Effects of chemical modifications on the surface- and protein-binding properties of the light chain of human high molecular weight kininogen. J Biol Chem 1987; 262: 3074-3081
    PubMedSearch in Google Scholar
  • 33 Scott CF, Silver LD, Schapira M, Colman RW. Cleavage of human high molecular weight kininogen markedly enhances its coagulant activity: evidence that this molecule exists as a procofactor. J Clin Invest 1984; 73: 954-962
    CrossrefPubMedSearch in Google Scholar
  • 34 Israels ED, Nisli G, Paraskevas F, Israels LG. Platelet Fc receptor as a mechanism for Ag-Ab complex-induced platelet injury. Thromb Diathes Haemorrh 1973; 29: 434-444
    PubMedSearch in Google Scholar
  • 35 Henson PM, Spiegelberg HL. Release of serotonin from human platelets induced by aggregated immunoglobulins of different classes and subclasses. J Clin Invest 1973; 52: 1282-1288
    CrossrefPubMedSearch in Google Scholar
  • 36 Pfueller SL, Weber S, Luscher EF. Studies of the mechanism of the human platelet release reaction induced by immunological stimuli: relationship between the binding of soluble IgG aggregates to the Fc receptor and cell response in the presence and absence of plasma. J Immunology 1973; 118: 514-524
    PubMedSearch in Google Scholar
  • 37 Cheng CM, Hawiger J. Affinity isolation and characterization of immunoglobulin G Fc fragment-binding glycoprotein from human blood platelets. J Biol Chem 1979; 254: 2165-2167
    PubMedSearch in Google Scholar